Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 7020-7027

  Cheung, Irene Y ^a   Feng, Yi ^a   Gerald, William ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 1; CYCLIN D1; GAMMA AMINOBUTYRIC ACID A RECEPTOR, BETA 3; HOMEODOMAIN PROTEIN; ISL LIM HOMEOBOX 1; KINESIN 1; KINESIN FAMILY MEMBER 1A; PAIRED LIKE HOMEOBOX 2B; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BONE MARROW; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; EVALUATION; GENE EXPRESSION PROFILING; GENETICS; INFANT; MICROARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY;

BONE MARROW; GENE EXPRESSION PROFILING; HUMANS; INFANT; MICROARRAY ANALYSIS; NEOPLASM, RESIDUAL; NEUROBLASTOMA; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58149241013     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0541     Document Type: Article

References (18)

1. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087-93.
2. Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 2003;21:3853-8.
3. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-801.
4. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 2003;12:435- 42.
5. Cheung IY, Vickers A, Cheung NK. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer 2006;119:152-6.
6. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998;4:2801-5.
7. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
8. Cheung I, Feng Y, Danis K, et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007;13:6978-83.
9. Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn 2007;9:237-41.
10. Alaminos M, Mora J, Cheung NK, et al. Genomewide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003;63:4538-46.
11. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-94.
12. Cheung IY, Cheung NKV. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 1997;3:821-6.
13. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001; 7:1698-705.
14. Fischer M, Skowron M, Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 2005;7:89-96.
15. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998;51:1-7.
16. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 2003;36:242-9.
17. Bozzi F, Luksch R, Collini P, et al. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma. Diagn Mol Pathol 2004;13:135-43.
18. Mosse YP, Laudenslager M, Khazi D, et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 2004;75:727-30.